{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:51:05Z","timestamp":1790812265441,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"PTCbio - IIS","award":["75"],"award-info":[{"award-number":["75"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01295-x","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T05:39:47Z","timestamp":1745213987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Novel Therapeutics for Familial Chylomicronemia Syndrome"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-2623","authenticated-orcid":false,"given":"Maria Cristina","family":"Izar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-4598","authenticated-orcid":false,"given":"Francisco Antonio Helfenstein","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"1295_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1042\/CS20070308","volume":"114","author":"EM Ooi","year":"2008","unstructured":"Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci. 2008;114:611\u201324. https:\/\/doi.org\/10.1042\/CS20070308.","journal-title":"Clin Sci."},{"key":"1295_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","volume":"275","author":"P Moulin","year":"2018","unstructured":"Moulin P, Dufour R, Averna M, Arca M, Cefalu AB, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an \u201cFCS score.\u201d Atherosclerosis. 2018;275:265\u201372. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.814.","journal-title":"Atherosclerosis."},{"issue":"4","key":"1295_CR3","doi-asserted-by":"publisher","first-page":"20230203","DOI":"10.36660\/abc.20230203","volume":"120","author":"MCO Izar","year":"2023","unstructured":"Izar MCO, Santos-Filho RD, Assad MHV, Chagas ACP, Toledo-J\u00fanior AO, Nogueira ACC, et al. Brazilian position statement for familial chylomicronemia syndrome \u2013 2023. Arq Bras Cardiol. 2023;120(4):20230203. https:\/\/doi.org\/10.36660\/abc.20230203.","journal-title":"Arq Bras Cardiol."},{"key":"1295_CR4","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","volume":"12","author":"M Davidson","year":"2018","unstructured":"Davidson M, Stevenson M, Hsieh A, Ahmad Z, Roeters van Lennep J, Crowson C, Witzum JL. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study. J Clin Lipidol. 2018;12:898\u2013907. https:\/\/doi.org\/10.1016\/j.jacl.2018.04.009.","journal-title":"J Clin Lipidol."},{"issue":"5","key":"1295_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jacl.2021.10.004","volume":"15","author":"RD Santos","year":"2021","unstructured":"Santos RD, Lorenzatti A, Corral P, Nogueira JP, Cafferata AM, Aimone D, et al. Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: an expert panel discussion. J Clin Lipidol. 2021;15(5):620\u20134. https:\/\/doi.org\/10.1016\/j.jacl.2021.10.004.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"1295_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2015.26","volume":"11","author":"AJ Brahm","year":"2015","unstructured":"Brahm AJ, Hegele RA. Chylomicronaemia - current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352\u201362. https:\/\/doi.org\/10.1038\/nrendo.2015.26.","journal-title":"Nat Rev Endocrinol"},{"key":"1295_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","volume":"23","author":"E Stroes","year":"2017","unstructured":"Stroes E, Moulin P, Parhofer KG, Rebours V, Lohr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl. 2017;23:1\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2016.10.002.","journal-title":"Atheroscler Suppl"},{"issue":"12","key":"1295_CR8","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1210\/js.2019-00214","volume":"3","author":"L O\u2019Dea","year":"2019","unstructured":"O\u2019Dea L, St L, MacDougall J, Alexander VJ, Digenio A, Hubbard B, Arca M, et al. Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles. J Endocr Soc. 2019;3(12):2397\u2013410. https:\/\/doi.org\/10.1210\/js.2019-00214.","journal-title":"J Endocr Soc"},{"key":"1295_CR9","doi-asserted-by":"publisher","first-page":"593931","DOI":"10.3389\/fendo.2020.593931","volume":"11","author":"RB Goldberg","year":"2020","unstructured":"Goldberg RB, Chait A. A comprehensive update on the chylomicronemia syndrome. Front Endocrinol. 2020;11:593931. https:\/\/doi.org\/10.3389\/fendo.2020.593931.","journal-title":"Front Endocrinol"},{"issue":"24","key":"1295_CR10","doi-asserted-by":"publisher","first-page":"00251","DOI":"10.1016\/j.jacl.2024.09.008","volume":"S1933\u20132874","author":"R Hegele","year":"2024","unstructured":"Hegele R, Ahmad Z, Ashraf A, Baldassarra A, Brown AS, Chait A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. J Clin Lipidol. 2024;S1933\u20132874(24):00251\u20134. https:\/\/doi.org\/10.1016\/j.jacl.2024.09.008.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"1295_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","volume":"12","author":"L Williams","year":"2018","unstructured":"Williams L, Rhodes KS, Karmally W, Welstead LA, Alexander L, Sutton L. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span. J Clin Lipidol. 2018;12(4):908\u201319. https:\/\/doi.org\/10.1016\/j.jacl.2018.04.010.","journal-title":"J Clin Lipidol"},{"key":"1295_CR12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3390\/children8111078","volume":"8","author":"A Thajer","year":"2021","unstructured":"Thajer A, Skacel G, de Gier C, Greber-Platzer S. The effect of a fat-restricted diet in four patients with familial chylomicronemia syndrome: a long-term follow-up study. Children. 2021;8:1078. https:\/\/doi.org\/10.3390\/children8111078.","journal-title":"Children"},{"key":"1295_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/J.JACL.2012.08.007","volume":"6","author":"JB Christian","year":"2012","unstructured":"Christian JB, Arondekar B, Buysman EK, Johnson SL, Seeger JD, Jacobson TA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg\/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6:450\u201361. https:\/\/doi.org\/10.1016\/J.JACL.2012.08.007.","journal-title":"J Clin Lipidol"},{"key":"1295_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/17512433.2022.2094768","volume":"15","author":"I Shamsudeen","year":"2022","unstructured":"Shamsudeen I, Hegele RA. Safety and efficacy of therapies for chylomicronemia. Expert Rev Clin Pharmacol. 2022;15:395\u2013405. https:\/\/doi.org\/10.1080\/17512433.2022.2094768.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"1295_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MOL.0b013e3283555a7e","volume":"23","author":"D Gaudet","year":"2012","unstructured":"Gaudet D, M\u00e9thot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012;23(4):310\u201320. https:\/\/doi.org\/10.1097\/MOL.0b013e3283555a7e.","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"1295_CR16","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1210\/jc.2011-3002","volume":"97","author":"AC Carpentier","year":"2012","unstructured":"Carpentier AC, Frisch F, Labb\u00e9 SM, Gagnon R, de Wal J, Greentree S, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97(5):1635\u201344. https:\/\/doi.org\/10.1210\/jc.2011-3002.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1295_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/gt.2012.43","volume":"20","author":"D Gaudet","year":"2013","unstructured":"Gaudet D, M\u00e9thot J, D\u00e9ry S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20(4):361\u20139. https:\/\/doi.org\/10.1038\/gt.2012.43.","journal-title":"Gene Ther"},{"issue":"2","key":"1295_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/dom.12002","volume":"15","author":"H Denison","year":"2013","unstructured":"Denison H, Nilsson C, Kujacic M, L\u00f6fgren L, Karlsson C, Knutsson M, et al. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first- time-in-human single-dose study. Diabetes Obes Metab. 2013;15(2):136\u201343. https:\/\/doi.org\/10.1111\/dom.12002.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1295_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/dom.12221","volume":"16","author":"H Denison","year":"2014","unstructured":"Denison H, Nilsson C, L\u00f6fgren L, Himmelmann A, M\u00e5rtensson G, Knutsson M, et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2014;16(4):334\u201343. https:\/\/doi.org\/10.1111\/dom.12221.","journal-title":"Diabetes Obes Metab"},{"key":"1295_CR20","doi-asserted-by":"publisher","unstructured":"Lomitapide. Am J Cardiovasc Drugs. 2011;11(5):347\u201352. https:\/\/doi.org\/10.2165\/11533560-000000000-00000.","DOI":"10.2165\/11533560-000000000-00000"},{"issue":"9860","key":"1295_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, Du Toit TH, Blom DJ, Hegele RA, Averna M, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in homozygous familial hypercholesterolemia HHS Public Access. Lancet. 2013;381(9860):40\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(12)61731-0.","journal-title":"Lancet"},{"issue":"3","key":"1295_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","volume":"174","author":"FM Sacks","year":"2014","unstructured":"Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years\u2019 treatment with lomitapide. JAMA Intern Med. 2014;174(3):443\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2013.13309.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"1295_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12020-020-02506-y","volume":"71","author":"AB Cefal\u00f9","year":"2020","unstructured":"Cefal\u00f9 AB, Giammanco A, Noto D, Spina R, Cabibi D, Barbagallo CM, Averna M. Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome. Endocrine. 2020;71(2):344\u201350. https:\/\/doi.org\/10.1007\/s12020-020-02506-y.","journal-title":"Endocrine."},{"key":"1295_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2022.08.017","volume":"359","author":"AB Cefal\u00f9","year":"2022","unstructured":"Cefal\u00f9 AB, D\u2019Erasmo L, Iannuzzo G, Noto D, Giammanco A, Montalli A, et al. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Atherosclerosis. 2022;359:13\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.08.017.","journal-title":"Atherosclerosis"},{"issue":"10","key":"1295_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","volume":"25","author":"I Gouni-Berthold","year":"2023","unstructured":"Gouni-Berthold I, Schwarz J, Berthold HK. Updates in drug treatment of severe hypertriglyceridemia. Curr Atheroscler Rep. 2023;25(10):701\u20139. https:\/\/doi.org\/10.1007\/s11883-023-01140-z.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"1295_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.12997\/jla.2024.13.1.2","volume":"13","author":"B Tomlinson","year":"2024","unstructured":"Tomlinson B, Wu QY, Zhong YM, Li YH. Advances in dyslipidaemia treatments: focusing on ApoC3 and ANGPTL3 inhibitors. J Lipid Atheroscler. 2024;13(1):2\u201320. https:\/\/doi.org\/10.12997\/jla.2024.13.1.2.","journal-title":"J Lipid Atheroscler."},{"key":"1295_CR27","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/14656566.2023.2206015","volume":"24","author":"CM Spagnuolo","year":"2023","unstructured":"Spagnuolo CM, Hegele RA. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. Expert Opin Pharmacother. 2023;24:1013\u201320. https:\/\/doi.org\/10.1080\/14656566.2023.2206015.","journal-title":"Expert Opin Pharmacother"},{"key":"1295_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg- HA. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1308027.","journal-title":"N Engl J Med"},{"key":"1295_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung and Blood Institute, Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1307095.","journal-title":"N Engl J Med."},{"key":"1295_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MOL.0000000000000764","volume":"32","author":"DS Ng","year":"2021","unstructured":"Ng DS. Evolving ANGPTL-based lipid-lowering strategies and beyond. Curr Opin Lipidol. 2021;32:271\u20132. https:\/\/doi.org\/10.1097\/MOL.0000000000000764.","journal-title":"Curr Opin Lipidol."},{"key":"1295_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377:211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1612790.","journal-title":"N Engl J Med"},{"key":"1295_CR32","doi-asserted-by":"publisher","first-page":"1479e90","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell TA, Fu W, Mullick AE, Alexander VJ, et al. Antisense oligonucleotide inhibition of apolipoprotein CIII reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479e90. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.300367.","journal-title":"Circ Res"},{"key":"1295_CR33","doi-asserted-by":"publisher","first-page":"706e13","DOI":"10.1194\/jlr.m066399","volume":"57","author":"X Yang","year":"2016","unstructured":"Yang X, Lee S-R, Choi Y-S, Alexander VJ, Digenio A, Yang Q, et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res. 2016;57:706e13. https:\/\/doi.org\/10.1194\/jlr.m066399.","journal-title":"J Lipid Res"},{"key":"1295_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinha-gen-Thiessen E, Moriarty PM, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:264\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(21)00046-2.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1295_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"key":"1295_CR36","doi-asserted-by":"publisher","unstructured":"Witztum JL, Gaudet D, Arca M, Jones A, Soran H, Gouni- Berthold I, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. J Clin Lipidol. 2023;17. https:\/\/doi.org\/10.1016\/J.JACL.2023.03.007.","DOI":"10.1016\/J.JACL.2023.03.007"},{"key":"1295_CR37","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/DC16-0126","volume":"39","author":"A Digenio","year":"2016","unstructured":"Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39:1408\u201315. https:\/\/doi.org\/10.2337\/DC16-0126.","journal-title":"Diabetes Care"},{"key":"1295_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/J.JACL.2022.08.008","volume":"16","author":"EA Oral","year":"2022","unstructured":"Oral EA, Garg A, Tami J, Huang EA, O\u2019Dea LSL, Schmidt H, et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: volanesorsen in FPLD; The BROADEN Study. J Clin Lipidol. 2022;16:833\u201349. https:\/\/doi.org\/10.1016\/J.JACL.2022.08.008.","journal-title":"J Clin Lipidol"},{"key":"1295_CR39","doi-asserted-by":"publisher","unstructured":"Prohaska TA, Alexander VJ, Karwatowska-Prokopczuk E, Tami J, Xia S, Witztum JL, et al. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. J Clin Lipidol. 2023;17. https:\/\/doi.org\/10.1016\/J.JACL.2023.04.007.","DOI":"10.1016\/J.JACL.2023.04.007"},{"key":"1295_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/J.ATHEROSCLEROSIS.2023.05.008","volume":"375","author":"A Jones","year":"2023","unstructured":"Jones A, Peers K, Wierzbicki AS, Ramachandran R, Mansfield M, Dawson C, et al. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS). Atherosclerosis. 2023;375:67\u201374. https:\/\/doi.org\/10.1016\/J.ATHEROSCLEROSIS.2023.05.008.","journal-title":"Atherosclerosis"},{"key":"1295_CR41","doi-asserted-by":"publisher","unstructured":"Tsimikas S, Ginsberg HN, Alexander VJ, Karwatowska-Prokopczuk E, Dibble A, Li L, et al. Differential effects of volanesorsen on ApoC-III, triglycerides and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or non-genetic criteria. J Clin Lipidol. 2024; https:\/\/doi.org\/10.1016\/j.jacl.2024.12.018","DOI":"10.1016\/j.jacl.2024.12.018"},{"key":"1295_CR42","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/EURHEARTJ\/EHAB890","volume":"43","author":"RA Hegele","year":"2022","unstructured":"Hegele RA. Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all? Eur Heart J. 2022;43:1413\u20135. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB890.","journal-title":"Eur Heart J"},{"key":"1295_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12944-024-02297-5","volume":"23","author":"E Karwatowska-Prokopczuk","year":"2024","unstructured":"Karwatowska-Prokopczuk E, Lesogor A, Yan JH, Hoenlinger A, Margolskee A, Li L, Tsimikas S. Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans. Lip Health Dis. 2024;23:329. https:\/\/doi.org\/10.1186\/s12944-024-02297-5.","journal-title":"Lip Health Dis"},{"issue":"19","key":"1295_CR44","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"A Bergmark","year":"2024","unstructured":"Bergmark A, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024;390(19):1770\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2402309.","journal-title":"N Engl J Med"},{"key":"1295_CR45","doi-asserted-by":"publisher","first-page":"107246","DOI":"10.1016\/j.phrs.2024.107246","volume":"205","author":"S Surma","year":"2024","unstructured":"Surma S, Shapiro MD, Banach M. Breaking new ground in lipid management: insights from the 2024 American College of Cardiology Scientific sessions. Pharmacol Res. 2024;205:107246. https:\/\/doi.org\/10.1016\/j.phrs.2024.107246.","journal-title":"Pharmacol Res"},{"key":"1295_CR46","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokoczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390:1781\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2400201.","journal-title":"N Engl J Med"},{"key":"1295_CR47","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","volume":"25","author":"I Gouni-Berthold","year":"2023","unstructured":"Gouni-Berthold I, Schwarz J, Berthold HK. Updates in Drug Treatment of Severe Hypertriglyceridemia. Curr Atherosclerosis Rep. 2023;25:701\u20139. https:\/\/doi.org\/10.1007\/s11883-023-01140-z.","journal-title":"Curr Atherosclerosis Rep"},{"key":"1295_CR48","doi-asserted-by":"publisher","unstructured":"Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, Scott R, et al. Abstract 12594: Pharmacodynamic effect of ARO- APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia. Circulation. 2020;142. https:\/\/doi.org\/10.1161\/CIRC.142.SUPPL_3.12594.","DOI":"10.1161\/CIRC.142.SUPPL_3.12594"},{"key":"1295_CR49","doi-asserted-by":"publisher","unstructured":"Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, Scott R, et al. Abstract 10357: ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia. Circulation. 2021;144. https:\/\/doi.org\/10.1161\/CIRC.144.SUPPL_1.10357.","DOI":"10.1161\/CIRC.144.SUPPL_1.10357"},{"issue":"7","key":"1295_CR50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620\u201330. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"1295_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa2409368","volume":"392","author":"GF Watts","year":"2025","unstructured":"Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, PALISADE Study Group, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2025;392(2):127\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2409368.","journal-title":"N Engl J Med."},{"key":"1295_CR52","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1705994","volume":"377","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377:296\u20137. https:\/\/doi.org\/10.1056\/NEJMc1705994.","journal-title":"N Engl J Med"},{"issue":"8","key":"1295_CR53","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"key":"1295_CR54","doi-asserted-by":"publisher","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29. https:\/\/doi.org\/10.1038\/S41591-023-02222-W.","DOI":"10.1038\/S41591-023-02222-W"},{"key":"1295_CR55","unstructured":"Efficacy and safety of evinacumab in adult patients with severe hypertriglyceridemia for the prevention of recurrent acute pancreatitis. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/ NCT04863014. Accessed 14 Jan 2025."},{"key":"1295_CR56","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham MJ, Lee RG, Brandt TA, Tai L-J, Fu W, Peralta R, et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 2017;377:222\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1701329.","journal-title":"N Engl J Med."},{"key":"1295_CR57","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41:3936\u201356. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa689.","journal-title":"Eur Heart J"},{"key":"1295_CR58","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145:1377\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059266.","journal-title":"Circulation"},{"issue":"9","key":"1295_CR59","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","volume":"29","author":"GF Watts","year":"2023","unstructured":"Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023;29(9):2216\u201323. https:\/\/doi.org\/10.1038\/s41591-023-02494-2.","journal-title":"Nat Med"},{"key":"1295_CR60","unstructured":"Rosenson RS, Gaudet D, Hegele R, Ballantyne CM, Nicholls S, Chang T, et al. ARO-ANG3, an investigational RNAi therapeutic, silences the expression of ANGPTL3 and decreases atherogenic lipoproteins in patients with mixed dyslipidemia: ARCHES-2 Study Results. American Heart Association Scientific Sessions. PR-APS.P4. Emerging Approaches to Lipid Lowering, Mo3213, 2023."},{"issue":"13","key":"1295_CR61","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0735-1097(24)03663-5","volume":"83","author":"KK Ray","year":"2024","unstructured":"Ray KK, Ruotolo G, Michael L, Shen X, Ma X, Lim S, et al. Solbinsiran, a GalNac-conjugated siRNA targeting ANGPTL3, reduces atherogenic lipoproteins in individuals with mixed dyslipidaemia in a durable and dose-dependent manner. J Am Coll Cardiol. 2024;83(13):1673. https:\/\/doi.org\/10.1016\/S0735-1097(24)03663-5.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"1295_CR62","doi-asserted-by":"publisher","first-page":"e160607","DOI":"10.1172\/jci.insight.160607","volume":"7","author":"MR Taskinen","year":"2022","unstructured":"Taskinen MR, Bjornson E, Matikainen N, S\u00f6derlund S, Ramo J, Ainola MM, et al. Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations. JCI Insight. 2022;7(19):e160607. https:\/\/doi.org\/10.1172\/jci.insight.160607.","journal-title":"JCI Insight"},{"key":"1295_CR63","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317686","volume":"127","author":"M Guo","year":"2020","unstructured":"Guo M, Xu Y, Dong Z, Zhou Z, Cong N, Gao M, et al. Inactivation of ApoC3 by CRISPR\/Cas9 protects against atherosclerosis in hamsters. Circ Res. 2020;127:1456\u20138. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317686.","journal-title":"Circ Res"},{"key":"1295_CR64","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12944-021-01605-7","volume":"20","author":"Y Zha","year":"2021","unstructured":"Zha Y, Lu Y, Zhang T, Yan K, Zhuang W, Liang J, et al. CRISPR\/Cas9-mediated knockout of APOC3 stabilizes plasma lipids and inhibits atherosclerosis in rabbits. Lipids Health Dis. 2021;20:180. https:\/\/doi.org\/10.1186\/s12944-021-01605-7.","journal-title":"Lipids Health Dis"},{"key":"1295_CR65","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","volume":"137","author":"AC Chadwick","year":"2018","unstructured":"Chadwick AC, Evitt NH, Lv W, Musunuru K. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3. Circulation. 2018;137:975\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031335.","journal-title":"Circulation"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01295-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01295-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01295-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T05:39:49Z","timestamp":1745213989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01295-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01295-x","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"23 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No animal subjects were used in this study. All studies with human subjects are published and followed ethical, institutional standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"51"}}